ARDEA BIOSCIENCES (RDEA) rated Outperform with price target $29 by Mehta Partners
Mehta Partners rated Outperform ARDEA BIOSCIENCES (NASDAQ: RDEA) on 07/14/2010, when the stock price was $20.06. Since
then, ARDEA BIOSCIENCES has gained 59.32% as of 06/19/2012's recent price of $31.96. If you would have followed this Mehta Partners's recommendation on RDEA, you would have gained 59.32% of your investment in 706 days.
Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.
The reputation of Mehta Partners
rests on a body of work that began in 1980s with the aim of "maintaining a birds-eye view of the pharma, biotech and healthcare industry worldwide." Viren Mehta, founder and managing partner of Mehta Partners
, formulated this objective and emphasized that the Biotechnology and Pharmaceutical segments are ultimately indistinguishable parts of the BioPharma industry; and that BioPharma is a truly global industry that is best understood when viewed from a worldwide perspective.